Nothing Special   »   [go: up one dir, main page]

MA56553B1 - Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk - Google Patents

Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk

Info

Publication number
MA56553B1
MA56553B1 MA56553A MA56553A MA56553B1 MA 56553 B1 MA56553 B1 MA 56553B1 MA 56553 A MA56553 A MA 56553A MA 56553 A MA56553 A MA 56553A MA 56553 B1 MA56553 B1 MA 56553B1
Authority
MA
Morocco
Prior art keywords
btk
treating
pyrrolopyrimidinone
tetrahydropyranyl
amino
Prior art date
Application number
MA56553A
Other languages
English (en)
Other versions
MA56553A (fr
Inventor
Hiroaki Inagaki
Kiyoshi Nakayama
Jean-Marc Lapierre
Sudharshan Eathiraj
Nivedita Namdev
Brian Schwartz
Yusuke Ota
Takayuki Momose
Tomoyuki Tsunemi
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of MA56553A publication Critical patent/MA56553A/fr
Publication of MA56553B1 publication Critical patent/MA56553B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La demande concerne un composé de formule (i) : ou un sel, tautomère, promédicament, solvate ou polymorphe pharmaceutiquement acceptable de celui-ci, destiné à être utilisé dans un procédé de traitement d'un trouble btk ou de modulation de btk, dans lequel la btk est une btk mutante ( ex., mutant btk c481s)
MA56553A 2015-12-23 2015-12-23 Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk MA56553B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/000285 WO2017111787A1 (fr) 2015-12-23 2015-12-23 Tétrahydropyranyl-amino-pyrrolopyrimidinone et procédés d'utilisation associés

Publications (2)

Publication Number Publication Date
MA56553A MA56553A (fr) 2022-04-27
MA56553B1 true MA56553B1 (fr) 2023-04-28

Family

ID=59090991

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56553A MA56553B1 (fr) 2015-12-23 2015-12-23 Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk

Country Status (28)

Country Link
EP (2) EP3394065B1 (fr)
JP (1) JP6634520B2 (fr)
KR (2) KR102547188B1 (fr)
CN (2) CN113307811B (fr)
AU (3) AU2015417922B2 (fr)
CA (1) CA3008446C (fr)
CY (1) CY1124210T1 (fr)
DK (2) DK3394065T3 (fr)
ES (2) ES2868884T3 (fr)
FI (1) FI3882250T3 (fr)
HR (2) HRP20230379T1 (fr)
HU (2) HUE061761T2 (fr)
IL (2) IL259938B (fr)
LT (2) LT3882250T (fr)
MA (1) MA56553B1 (fr)
MD (1) MD3882250T2 (fr)
MX (1) MX2018007815A (fr)
MY (1) MY193177A (fr)
PH (1) PH12018501390B1 (fr)
PL (2) PL3882250T3 (fr)
PT (2) PT3394065T (fr)
RS (2) RS64141B1 (fr)
RU (1) RU2715421C2 (fr)
SA (1) SA518391836B1 (fr)
SG (1) SG11201805154YA (fr)
SI (2) SI3882250T1 (fr)
WO (1) WO2017111787A1 (fr)
ZA (1) ZA201804091B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190035925A (ko) 2016-08-24 2019-04-03 아르퀼 인코포레이티드 아미노-피롤로피리미디논 화합물 및 이의 사용 방법
CN109956870A (zh) 2017-12-14 2019-07-02 南京卡文迪许生物工程技术有限公司 一种罗沙司他的合成方法及其中间体化合物
AU2020283597A1 (en) * 2019-05-31 2021-11-25 Fochon Biosciences, Ltd. Substituted pyrrolo (2, 3-b) pyridine and pyrazolo (3, 4-b) pyridine derivatives as protein kinase inhibitors
EP4059935A4 (fr) * 2019-11-13 2024-02-28 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. Composé pyrrolopyrimidine utilisé comme inhibiteur de btk et son utilisation
CN112812100B (zh) * 2019-11-18 2022-04-05 四川海思科制药有限公司 一种具有降解btk激酶的化合物及其制备方法和药学上的应用
JP7011638B2 (ja) * 2019-12-16 2022-02-10 アークル インコーポレイテッド テトラヒドロピラニルアミノ-ピロロピリミジノンおよびその使用の方法
CN112608318B (zh) * 2019-12-16 2023-09-08 成都海博为药业有限公司 一种作为蛋白质激酶抑制剂的化合物及其用途
MX2023005761A (es) * 2020-11-17 2023-05-29 Fochon Biosciences Ltd Pirrolo [2,3-b] piridina sustituida y derivados de pirazolo [3,4-b] piridina como inhibidores de proteinas quinasas.
CN112574200B (zh) * 2021-02-26 2021-06-11 安润医药科技(苏州)有限公司 Btk和/或btk的突变体c481s的小分子抑制剂
CN115028633B (zh) * 2021-03-08 2023-12-22 药雅科技(上海)有限公司 吡咯并嘧啶类化合物的制备及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
WO2022213932A1 (fr) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 Composé de pyrrolopyrimidinone et son utilisation
CN117794934A (zh) 2021-05-12 2024-03-29 浙江龙传生物医药科技有限公司 吡咯并嘧啶类化合物的晶型及其制备方法
JP2025500886A (ja) 2021-12-14 2025-01-15 クロスファイアー オンコロジー ホールディング ビー.ヴイ. 大環状btk阻害剤
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715A (zh) * 2023-04-06 2023-07-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024246287A1 (fr) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Utilisation médicale d'un inhibiteur de btk réversible macrocyclique
WO2024245577A1 (fr) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Combinaisons thérapeutiques d'un inhibiteur irréversible de btk et d'un inhibiteur réversible de btk
WO2024245578A1 (fr) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Combinaisons thérapeutiques d'un inhibiteur de btk irréversible et d'un inhibiteur de btk réversible macrocyclique
WO2024256568A1 (fr) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Formes salines et formes cristallines d'un inhibiteur de btk macrocyclique
WO2024256574A1 (fr) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Procédé de préparation d'inhibiteurs de btk macrocycliques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO2011063159A1 (fr) 2009-11-18 2011-05-26 Plexxikon, Inc. Composés et méthodes utilisés pour la modulation des kinases et indications à cet effet
US8377946B1 (en) * 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
WO2014164729A1 (fr) * 2013-03-12 2014-10-09 Arqule, Inc. Composés tricycliques substitués de pyrazolo-pyrimidine
EP2970300B1 (fr) * 2013-03-15 2018-05-16 Boehringer Ingelheim International GmbH Composés hétéroaromatiques en tant qu'inhibiteurs btk
GB201309085D0 (en) * 2013-05-20 2013-07-03 Redx Pharma Ltd Compounds
GB201410430D0 (en) * 2014-06-11 2014-07-23 Redx Pharma Ltd Compounds

Also Published As

Publication number Publication date
EP3882250B1 (fr) 2023-02-15
FI3882250T3 (fi) 2023-04-27
MA56553A (fr) 2022-04-27
RU2018126793A3 (fr) 2020-01-23
EP3394065B1 (fr) 2021-04-07
CN108699062A (zh) 2018-10-23
KR102547188B1 (ko) 2023-06-26
ES2942743T3 (es) 2023-06-06
EP3394065A1 (fr) 2018-10-31
KR102746900B1 (ko) 2024-12-24
RS61887B1 (sr) 2021-06-30
IL282572B (en) 2022-04-01
IL259938A (en) 2018-07-31
EP3882250A1 (fr) 2021-09-22
PT3394065T (pt) 2021-05-06
CN113307811A (zh) 2021-08-27
PL3882250T3 (pl) 2023-09-11
PL3394065T3 (pl) 2021-08-02
AU2019201737A1 (en) 2019-04-04
WO2017111787A1 (fr) 2017-06-29
MX2018007815A (es) 2019-07-04
JP2018538349A (ja) 2018-12-27
SA518391836B1 (ar) 2022-06-19
RS64141B1 (sr) 2023-05-31
DK3394065T3 (da) 2021-05-31
EP3394065A4 (fr) 2019-07-10
AU2015417922A1 (en) 2018-06-28
SI3394065T1 (sl) 2021-08-31
RU2715421C2 (ru) 2020-02-28
CA3008446A1 (fr) 2017-06-29
CN108699062B (zh) 2021-06-29
HUE061761T2 (hu) 2023-08-28
AU2019201737B2 (en) 2020-03-05
SI3882250T1 (sl) 2023-07-31
KR20180096753A (ko) 2018-08-29
JP6634520B2 (ja) 2020-01-22
BR112018012828A2 (pt) 2018-12-04
CA3008446C (fr) 2023-10-10
AU2020203690A1 (en) 2020-06-25
IL259938B (en) 2021-05-31
ES2868884T3 (es) 2021-10-22
SG11201805154YA (en) 2018-07-30
PH12018501390B1 (en) 2022-06-10
MY193177A (en) 2022-09-26
CN113307811B (zh) 2023-11-14
RU2018126793A (ru) 2020-01-23
LT3882250T (lt) 2023-05-25
AU2015417922B2 (en) 2018-12-20
NZ743384A (en) 2024-05-31
PT3882250T (pt) 2023-04-21
HUE055221T2 (hu) 2021-11-29
CY1124210T1 (el) 2022-05-27
MD3882250T2 (ro) 2023-06-30
DK3882250T3 (da) 2023-05-22
PH12018501390A1 (en) 2019-02-27
HRP20210844T1 (hr) 2021-07-09
HRP20230379T1 (hr) 2023-06-23
LT3394065T (lt) 2021-06-25
IL282572A (en) 2021-06-30
ZA201804091B (en) 2019-03-27
KR20230098690A (ko) 2023-07-04
AU2020203690B2 (en) 2021-08-05

Similar Documents

Publication Publication Date Title
MA56553B1 (fr) Tétrahydropyranyl-amino-pyrrolopyrimidinone pour une utilisation dans un procédé de traitement d'un trouble médié par btk
MA52948B1 (fr) Composés
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
EA201891703A1 (ru) Соединения бензопиразола и их аналоги
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MA40302B1 (fr) Dérivés de carbazole
WO2015132799A3 (fr) Nouveaux composés hétérocycliques
EA202191519A1 (ru) Модуляторы trex1
MX2017008417A (es) Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1).
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MA40281B1 (fr) Composés de pyrazole et leur utilisation en tant qu' agents de blocage des canaux calciques de type t
EA201591291A1 (ru) Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MX2018010191A (es) Inhibidores de glucosidasa.
PE20170947A1 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
MA46337A (fr) Composé de pyridine
MA39427B1 (fr) Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète
MA39688A (fr) Composés hétéroaryle pour le traitement de maladies ophtalmiques
MA39983A (fr) Dérivés de carboxamide
MA44020B1 (fr) Composés antitumoraux
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.